Frontotemporal dementia (FTD) is a group of brain disorders caused by progressive nerve cell loss in the frontal and temporal lobes, the regions that control personality, behavior, and language. It is a leading cause of dementia in people under 65, with a prevalence of roughly 7.5 per 100,000 people in that age group. Unlike Alzheimer’s disease, which typically starts with memory loss, FTD usually announces itself through striking changes in behavior or a gradual breakdown in the ability to speak and understand words.
How FTD Differs From Alzheimer’s Disease
The single most important distinction is what goes wrong first. Alzheimer’s disease usually begins with difficulty learning and retaining new information. A person with early Alzheimer’s may forget recent conversations, misplace things, or struggle to recall names. In contrast, someone with early FTD generally knows the day and time, can keep track of recent events, and remembers what happened yesterday. Their problems lie elsewhere.
FTD often begins with socially inappropriate behavior, apathy, or impulsive actions. People with early Alzheimer’s tend to remain socially skillful and may even become adept at covering up their difficulties. Someone with FTD may lose that social polish entirely, making rude comments, ignoring basic hygiene, or becoming emotionally flat in situations that would normally provoke a reaction. Age matters too: the odds of Alzheimer’s increase sharply with age, while FTD is more likely to appear in a person’s 50s or early 60s. The average age of onset varies by genetic subtype but clusters around the late 50s to early 60s.
The Main Subtypes of FTD
FTD is not a single disease. It comes in several forms, each targeting different brain circuits and producing different symptoms.
Behavioral Variant FTD
This is the most common form. It targets the frontal lobes and the inner (medial) parts of the temporal lobes, along with deeper brain structures involved in motivation, reward, and emotional processing. The result is a fundamental shift in personality. Some people become disinhibited, making inappropriate comments, displaying a silly or punning sense of humor, or acting impulsively. Others go in the opposite direction, becoming deeply apathetic, speaking little, and withdrawing from the world around them. Loss of empathy is common, and many people develop compulsive behaviors or dramatic changes in eating habits, such as binge eating or fixating on sweets.
Semantic Variant (Semantic Dementia)
This form attacks the front portions of both temporal lobes. Speech remains fluent, but the meaning of words gradually drains away. A person might look at a common object like a comb and not know what it is or what it’s for. They lose the ability to understand even single words, though they can still repeat sentences and produce grammatically correct speech. It’s as if the brain’s dictionary is being erased page by page.
Nonfluent Variant
Here the damage centers on the left side of the brain, in areas responsible for speech production. Speaking becomes effortful and halting, with sound errors and distorted pronunciation. Grammar breaks down. A person might drop small connecting words, producing telegraphic sentences. They can still understand simple statements, but complex sentences with multiple clauses become hard to follow. Over time, some people progress to near-total muteness.
Logopenic Variant
This less common form produces word-finding pauses in otherwise fluent speech. The person knows what they want to say but cannot retrieve the right word. Damage is concentrated in the left posterior temporal and parietal regions. Comprehension of simple items remains intact, but the constant searching for words makes conversation increasingly frustrating.
What Happens in the Brain
At the cellular level, FTD is driven by abnormal clumps of protein building up inside nerve cells. Two proteins account for the vast majority of cases. The first is tau, a protein that normally helps stabilize the internal scaffolding of neurons. In FTD, tau becomes chemically altered and clumps together, disrupting cell function. The second is TDP-43, a protein that normally helps manage genetic instructions inside the cell nucleus. In FTD, TDP-43 disappears from the nucleus and forms toxic clusters in the surrounding cell body. A third protein called FUS causes a small minority of cases.
Which protein is involved cannot be determined from symptoms alone. The behavioral variant, for example, can be caused by either tau or TDP-43 accumulation. This matters because treatments currently in development tend to target one specific protein, making accurate biological diagnosis increasingly important.
Genetics and Family History
FTD has a stronger genetic component than most other dementias. Three genes account for the majority of inherited cases. The most common is C9orf72, a gene in which a short DNA sequence repeats far more times than it should. This mutation is found in roughly 25% of people with a family history of FTD and is also the most common genetic cause of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease). The second gene, MAPT, directly produces the tau protein and tends to cause disease at a younger age, with an average onset around 49.5 years. The third, GRN, produces a protein called progranulin and is associated with a somewhat later onset, averaging around 61 years.
Not everyone with FTD has a family history of the disease. Many cases appear to arise without a clear inherited mutation. But if a first-degree relative had FTD or ALS, the risk is meaningfully higher, and genetic counseling can help clarify whether testing makes sense.
The Overlap With Motor Diseases
FTD does not always stay confined to thinking and behavior. It frequently overlaps with motor disorders, creating combinations that can be confusing to diagnose. The most well-known overlap is with ALS, which destroys the motor neurons controlling voluntary movement. When FTD and ALS occur together, the disease typically progresses faster, with a median survival of about three years from diagnosis.
Two other motor conditions fall under the FTD umbrella. Progressive supranuclear palsy (PSP) produces a symmetric stiffness and slowness of movement, along with difficulty looking up and down. Corticobasal syndrome causes markedly lopsided symptoms: one arm or leg may become stiff, clumsy, and difficult to control voluntarily, sometimes feeling as though it moves on its own (a phenomenon called alien limb). Both PSP and corticobasal syndrome are strongly linked to tau protein accumulation.
How FTD Is Diagnosed
There is no single blood test or scan that confirms FTD. Diagnosis relies on a combination of clinical assessment and brain imaging, with three levels of certainty: possible, probable, and definite.
For the behavioral variant, a diagnosis of “possible” requires progressive deterioration in behavior plus at least three of six core features: disinhibition, apathy, loss of empathy, changes in eating behavior, compulsive or ritualistic behaviors, and a pattern of difficulty with planning and problem-solving that outweighs memory problems. A “probable” diagnosis adds supporting evidence from brain imaging, typically an MRI showing shrinkage in the frontal or anterior temporal lobes, or a PET scan showing reduced activity in those same regions.
For the language variants, the starting point is confirming that language difficulty is the most prominent problem, that it impairs daily activities, and that it was the first major symptom to appear. From there, specific patterns of preserved and impaired abilities distinguish the semantic, nonfluent, and logopenic forms. Brain imaging can support each diagnosis by showing atrophy in the expected location: anterior temporal lobes for the semantic variant, left posterior frontal areas for the nonfluent variant, and left posterior temporal and parietal areas for the logopenic variant.
Misdiagnosis is common, particularly in the behavioral variant. Because personality changes can resemble depression, bipolar disorder, or even a midlife crisis, people with FTD often see psychiatrists for years before the correct diagnosis is made.
Treatment and Day-to-Day Management
No medication slows or stops FTD. There are no FDA-approved or European Medicines Agency-approved disease-modifying treatments, and the drugs used for Alzheimer’s disease can actually make things worse. Donepezil, frequently prescribed for Alzheimer’s, has been shown in multiple studies to worsen behavioral symptoms in FTD without improving cognition. Memantine, another common Alzheimer’s drug, is also ineffective.
Current treatment focuses entirely on managing symptoms with off-label medications and non-drug strategies. For behavioral symptoms like impulsivity, compulsive eating, rigid thinking, and loss of empathy, certain antidepressants that boost serotonin are the most commonly recommended option. For more dangerous behaviors like physical aggression, self-harm, or severe agitation, low-dose antipsychotics are sometimes used, though carefully, given their side-effect profile in people with dementia. Apathy, one of the most disabling and difficult-to-treat symptoms, has fewer reliable pharmacological options.
Non-drug approaches play a major role. Structured daily routines reduce confusion and agitation. Simplifying the environment, removing triggers for compulsive behavior, and redirecting rather than confronting can help caregivers manage difficult moments. Speech therapy can help people with the language variants maintain communication skills longer, and occupational therapy can preserve daily functioning as the disease progresses.
Prognosis and What to Expect
FTD is a progressive, life-shortening disease. Median survival from diagnosis ranges from about 7 to 13 years in clinical studies, though individual variation is wide. When FTD occurs alongside motor neuron disease, the timeline compresses significantly to a median of roughly 3 years, though some people in that group survive up to 5 years. Survival does not appear to depend on age at onset or how severe the dementia is at the time of diagnosis.
The most common causes of death are pneumonia, cardiovascular failure, choking, and severe weight loss (cachexia). Sudden and accidental deaths are also not uncommon, a reflection of the impulsivity and poor judgment that characterize some forms of the disease. As FTD advances, most people eventually need full-time care, and the burden on family caregivers is among the highest of any dementia, partly because the disease strikes at a younger age when families may still have dependent children and active careers.